Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer-Reference-Cited by-同舟云学术

Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer

Published:2021-01-13 Issue:4 Volume:60 Page:549-553
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Bregni Giacomo¹,Vandeputte Caroline²,Pretta Andrea¹,Senti Chiara¹,Trevisi Elena¹,Acedo Reina Elena²,Kehagias Pashalina²,Liberale Gabriel³^ORCID,Moretti Luigi⁴,Bali Maria Antonietta⁵,Demetter Pieter⁶,Flamen Patrick⁷,Carrasco Javier⁸,D'Hondt Lionel⁹,Geboes Karen¹⁰,Gokburun Yeter¹¹,Peeters Marc¹²,Van den Eynde Marc¹³,Van Laethem Jean-Luc¹⁴,Vergauwe Philippe¹⁵,Chapot Camille Anastasia¹⁶,Buyse Marc¹⁷,Deleporte Amelie¹,Hendlisz Alain¹,Sclafani Francesco¹

Affiliation:

1. Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium

2. GUTS Lab, Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium

3. Department of Surgery, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium

4. Department of Radiotherapy, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium

5. Department of Radiology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium

6. Department of Pathology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium

7. Department of Nuclear Medicine, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium

8. Grand Hôpital de Charleroi, Charleroi, Belgium

9. CHU UCL Namur, Site Godinne, Yvoir, Belgium

10. Department of Gastroenterology, Universitair Ziekenhuis Gent, Ghent, Belgium

11. CHR Namur, Namur, Belgium

12. Department of Oncology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium

13. Institut Roi Albert II, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium

14. Hôpital Erasme - Université Libre de Bruxelles (ULB), Brussels, Belgium

15. AZ Groeninge, Groeninge, Belgium

16. Clinical Trial Support Unit (CTSU), Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium

17. International Drug Development Institute, Louvain-la-Neuve, Belgium

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2020.1871067

Reference16 articles.

1. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

3. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial

4. Immunogenic cell death in cancer and infectious disease

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy;British Journal of Cancer;2023-09-25

2. Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review;Frontiers in Pharmacology;2023-06-28

3. Therapeutic Effect of Shp2 Inhibition Combined with Regorafenib in Advanced Colorectal Cancer;2023

4. Pre-trial quality assurance of diffusion-weighted MRI for radiomic analysis and the role of harmonisation;Physica Medica;2022-11

5. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer;Cancer Treatment Reviews;2022-11